Struemper H - Search Results

1

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.

Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators. Österborg A, et al. Among authors: struemper h. Haematologica. 2015 Aug;100(8):e311-4. doi: 10.3324/haematol.2014.121459. Epub 2015 Mar 13. Haematologica. 2015. PMID: 25769539 Free PMC article. No abstract available.

2

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.

Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC. Struemper H, et al. J Clin Pharmacol. 2014 Jul;54(7):818-27. doi: 10.1002/jcph.268. Epub 2014 Jan 28. J Clin Pharmacol. 2014. PMID: 24443277 Clinical Trial.

3

Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.

Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Rathi C, et al. Among authors: struemper h. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):851-863. doi: 10.1002/psp4.12660. Epub 2021 Jul 29. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34076364 Free PMC article.

4

Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.

Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, Jewell RC. Ferron-Brady G, et al. Among authors: struemper h. Clin Pharmacol Ther. 2021 Nov;110(5):1282-1292. doi: 10.1002/cpt.2409. Epub 2021 Oct 4. Clin Pharmacol Ther. 2021. PMID: 34468979 Free PMC article. Clinical Trial.

5

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.

Collins J, van Noort M, Rathi C, Post TM, Struemper H, Jewell RC, Ferron-Brady G. Collins J, et al. Among authors: struemper h. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1411-1424. doi: 10.1002/psp4.13016. Epub 2023 Aug 2. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37465991 Free PMC article.

6

Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.

Simpkins F, Flores A, Chu C, Berek JS, Lucci J 3rd, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, Gardner O, Toso J, Coukos G. Simpkins F, et al. Among authors: struemper h. Cancer Immunol Res. 2013 Sep;1(3):168-78. doi: 10.1158/2326-6066.CIR-13-0098. Epub 2013 Jul 31. Cancer Immunol Res. 2013. PMID: 24777679 Clinical Trial.

7

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.

Yapa SW, Roth D, Gordon D, Struemper H. Yapa SW, et al. Among authors: struemper h. Lupus. 2016 Nov;25(13):1448-1455. doi: 10.1177/0961203316642309. Epub 2016 Jul 11. Lupus. 2016. PMID: 27072354 Free PMC article. Clinical Trial.

8

Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.

Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D. Tanaka Y, et al. Among authors: struemper h. Mod Rheumatol. 2019 May;29(3):452-460. doi: 10.1080/14397595.2018.1480915. Epub 2018 Jul 20. Mod Rheumatol. 2019. PMID: 29792370 Clinical Trial.

9

Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus.

Struemper H, Chen C, Cai W. Struemper H, et al. J Clin Pharmacol. 2013 Jul;53(7):711-20. doi: 10.1002/jcph.104. Epub 2013 May 16. J Clin Pharmacol. 2013. PMID: 23681782 Clinical Trial.

10

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.

Struemper H, Murtaugh T, Gilbert J, Barton ME, Fire J, Groark J, Fox NL, Roth D, Gordon D. Struemper H, et al. Clin Pharmacol Drug Dev. 2016 May;5(3):208-15. doi: 10.1002/cpdd.219. Epub 2015 Dec 4. Clin Pharmacol Drug Dev. 2016. PMID: 27163500 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters